VBL Therapeutics, a late-stage clinical biopharmaceutical company, has opened a gene-therapy manufacturing plant at its new headquarters in Modiin, Israel.

This plant will be the commercial facility for producing the company’s lead product candidate, ofranergene obadenovec (VB-111), for treating thyroid, ovarian, and lung cancers if approved.

The 20,000-square-foot facility is capable of manufacturing at large-scale capacity of 1,000 liters and is scalable to 2,000 liters. 

The investment in the facility is included in the company’s budget and was also supported by the Israel Innovation Authority, a group responsible for the country’s innovation policy, which has provided governmental grants to the project. VBL expects that its current cash will fund the company’s operating expenses and capital expenditure requirements into 2019.

Source: VBL Therapeutics